on Moderna, Inc. (NASDAQ:MRNA)
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
Moderna, Inc. (NASDAQ: MRNA) revealed that three abstracts focusing on the investigational mRNA therapy mRNA-4157 (V940) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago, IL. This therapy is being co-developed with Merck (MSD outside the United States and Canada).
The studies include:
1. Abstract #TPS9616 examines pembrolizumab with V940 versus pembrolizumab with placebo for treating high-risk stage II-IV melanoma. Presented by Dr. Jeffrey S. Weber on June 1.
2. Abstract #TPS8116 details a Phase 3 study of V940 and pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Presented by Dr. Jay M. Lee on June 1.
3. Abstract #LBA9512 provides a 3-year update on mRNA-4157 in resected melanoma. Presented by Dr. Jeffrey S. Weber on June 3.
Moderna will host an investor webcast on June 3 from 6:15 to 7:15 PM CDT to discuss these findings. The webcast will be available on Moderna's website and archived for 30 days.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Moderna, Inc. news